Incruse ^*

Incruse Ellipta is a prescription medication used for the long-term, once-daily maintenance treatment of chronic obstructive pulmonary disease (COPD). This includes conditions like emphysema and chronic bronchitis. It helps to relax the airway muscles, making it easier to breathe. It is not intended for the relief of sudden breathing problems and is not a rescue inhaler.

Incruse Ellipta begins to work after the first dose, helping to open airways within about 15 minutes. However, it is designed for long-term control, not immediate relief. Patients typically notice the full, stable benefit of easier breathing and symptom reduction after several days of consistent daily use. You should use it every day as prescribed to get the best results.

No, you should not use Incruse more than once a day. The medication is specifically formulated to provide 24-hour symptom relief with just a single inhalation every 24 hours. Taking more than the prescribed dose will not improve its effectiveness and can significantly increase your risk of experiencing serious side effects. Always follow your doctor’s instructions.

If you miss a dose of Incruse, you should take it as soon as you remember. However, if it is almost time for your next scheduled dose, just skip the missed one. Do not take two doses at the same time or close together to make up for the missed one. Simply resume your regular once-daily schedule.

No, Incruse Ellipta is not a steroid. It is an anticholinergic medication, with the active ingredient umeclidinium. It works by relaxing the muscles around the airways. This is a different mechanism from inhaled corticosteroids (steroids), which work by reducing inflammation. Some COPD combination inhalers contain a steroid, but Incruse does not.

Incruse can often be used with other inhalers, such as a rescue inhaler for sudden symptoms. However, you should not use it with other medicines that contain a long-acting anticholinergic, as this may increase the risk of side effects. Always inform your doctor about all the medications you are taking, including other inhalers, so they can manage your treatment safely.

The most common side effects reported with Incruse include upper respiratory tract infections, presenting as common cold symptoms like a stuffy nose or sore throat. Other frequent side effects are coughing and joint pain. These effects are typically mild and may not be experienced by everyone. If any side effect becomes severe or bothersome, you should contact your doctor.

Weight gain is not recognized as a common side effect of Incruse Ellipta. Medications that are well-known for causing weight gain, such as oral corticosteroids, work differently. As an inhaled anticholinergic, Incruse has not been linked to changes in body weight in clinical trials. If you notice significant weight changes, discuss them with your doctor to identify the cause.

There is no direct interaction listed between Incruse and alcohol. However, for people with COPD, heavy alcohol consumption can sometimes interfere with breathing or lead to other health complications. It is best to consume alcohol only in moderation. You should discuss your drinking habits with your doctor to ensure it is safe for your overall health condition.

Your Incruse Ellipta inhaler should be stored at room temperature in a dry place, away from direct heat or sunlight. It should remain in its sealed foil tray until you are ready for its first use. After you open the tray, the inhaler must be used within six weeks. Always keep the inhaler’s cover closed to protect it from dirt and moisture.

Incruse and Spiriva are both once-daily anticholinergic inhalers prescribed for COPD, but they contain different active ingredients. Incruse contains umeclidinium, while Spiriva contains tiotropium. While both work in a similar way to relax airway muscles, some patients may respond better to one than the other. Your doctor will choose the medication best suited for your specific needs.

Incruse has the potential to worsen a condition known as narrow-angle glaucoma, as it can increase pressure inside the eye. If you have a history of eye problems, you must inform your doctor before starting this medication. If you experience eye pain, blurred vision, or see halos while using Incruse, report it to your doctor immediately as it can be a medical emergency.

No, you do not need to rinse your mouth after using Incruse. Rinsing the mouth is a common instruction for inhaled corticosteroids to prevent a mouth infection called thrush. Since Incruse is an anticholinergic and does not contain a steroid, the risk of thrush is not a concern, and rinsing is not necessary.

Your Incruse Ellipta inhaler is equipped with a dose counter on the front. It shows you exactly how many doses are left in the device. The number will decrease by one each time you open the cover. When the dose counter displays a "0", the inhaler is empty, and you should dispose of it properly and start a new one.

No, Incruse is not approved for the treatment of asthma. The safety and effectiveness of Incruse in people with asthma have not been established. It is specifically a maintenance treatment for chronic obstructive pulmonary disease (COPD). Using it for asthma could be unsafe. Always use medications only as prescribed by your healthcare provider for the specified condition.